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ABSTRACT
Booster inﬂuenza vaccination has been recommended for patients with chronic renal disease in order
to enhance the immune response to the inﬂuenza vaccine; however, the efﬁcacy of a booster
inﬂuenza vaccination is a matter of controversy. Therefore, we made a meta-analysis to determine the
efﬁcacy in patients with hemodialysis (HD), peritoneal dialysis (PD) and renal transplant recipient (RT).
The sero-protection rate was used as a serologic parameter to describe the immune response to the
vaccine. Statistical analysis was performed to calculate the pooled rate difference (RD) and 95%
conﬁdence interval (CI). The pooled RD for the H1N1, H3N2 and B inﬂuenza vaccines was 0.02 (95% CI:
¡0.02–0.06), 0.05 (95% CI: ¡0.01–0.11), 0.04 (95% CI: ¡0.02–0.10), respectively. We concluded that a
booster dose of the inﬂuenza vaccine did not effectively enhance immunogenicity. Therefore, a
booster dose of vaccine is not recommended for patients with hemodialysis, peritoneal dialysis and
renal transplant recipients.
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Introduction
Inﬂuenza leads to a substantial increase in morbidity and mor-
20 tality each year. Worldwide, inﬂuenza infection causes 3–5 -
million severe illnesses and 250,000–500,000 deaths annually.1
Patients with chronic renal disease have a higher mortality rate
than the general population. Compared with the general popu-
lation, the annual mortality rate for sepsis is 20-fold higher in
25 transplant recipients and 100 to 300-fold higher in dialysis
patients.2 Because chronic renal disease patients have compro-
mised immunity, they are vulnerable to inﬂuenza infection.3,4
Moreover, inﬂuenza infection results in severe complications.
Inﬂuenza infection is a signiﬁcant threat to this population of
30 patients. For the above reasons, these patients beneﬁt from pre-
vention of inﬂuenza infection more so than the general
population.
In healthy people the inﬂuenza vaccination is safe and
effective, but challenges exist when the inﬂuenza vaccine is
35 administered to patients with chronic renal disease. Indeed,
it has been reported that the inﬂuenza vaccine has weakened
efﬁcacy in patients with chronic renal disease.5 Under such
circumstances, many strategies have been proposed to
strengthen the immunogenicity of the inﬂuenza vaccine; a
40 booster vaccination is one compelling example. Although
this measure was implemented in 1987 by Versluis et al.,6
the anticipated effect has not been clearly established in these
patients. The booster vaccination means increasing the inﬂu-
enza antigen supply to patients with chronic renal disease,
45which would accelerate depletion of the limited global inﬂu-
enza antigen supply.
The beneﬁt of a booster vaccination has been a matter of
controversy in patients with HD, PD and RT. Only a few stud-
ies have addressed this issue, and the reliability of the studies
50was limited because of the small number of patients. A meta-
analysis is thus a useful tool to collate the scattered evidence.
In the current study we determined the efﬁcacy of a booster
inﬂuenza vaccination in patients with chronic renal disease,
including patients undergoing hemodialysis, peritoneal dialysis,
55and kidney transplantation, and veriﬁed the clinical beneﬁt of a
booster inﬂuenza vaccination.
Results
Literature review
Three hundred 3 relevant records were retrieved from the
60China National Knowledge Infrastructure (CNKI), Pubmed,
Cochrane Library, Embase, and ScienceDirect databases. Only
nine full text articles were eligible after screening. All of the
studies were cohort studies. The quality of all studies was >5
stars. The details of the process are shown in Figure 1.
65Three records from Germany collected data during the same
season and in the same location.7-9 We had doubts that
the data came from one population. Similarly, 2 records from
The Netherlands were based on data collection during the same
season and in the same location.6,10 Under such conditions, we
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70 abstracted information from one study that had the most
detailed data to avoid pooling the data from overlapping
populations.
Description of included studies
The eligible publications included 2 from The Netherlands, 2
75 from Belgium, and one each from Italy, Korea, Spain, Germany,
and France (Table 1). All of the papers were published between
1987 and 2013. Most of the patients who were recruited in the
studies were elderly. The exact number of patients could not be
derived from the original studies. In only one study was a com-
80parison (ﬁrst vs. booster vaccination) made between different
groups of patients.11
The vaccine used in all the studies was monovalent or
trivalent, and administered via the intramuscular route
Figure 1. Flow chart of study selection.
Table 1. Description of characteristics of the included studies.
First Author
year of
publication study year country population Age F/M
Interval between transplantation
and vaccination (years)
Years on
dialysis NOS
Beyer 1987 1985–1986 Netherlands HD 57(17,76) 55/53 NA 2(0.2,12) S2;C2;O3;T7
Vogtlander 2004 1998–1999 Netherlands HD 70 22/22 NA 2.7 S4;C2;O2;T8
Tanzi 2007 2003–2004 Italy HD 65.3 § 13.5 23/35 NA NA S0;C2;O3;T5
Song 2006 2003–2004 Korea HD 50.0 § 6.9 17/23 NA 2.2§ 1.1 S4;C1;O2;T7
HD_C 48.6 § 6.7 25/20 NA 1.8§ 0.8
Scharpe 2009 2003–2004 Belgium HD 67 § 14 79/122 NA 3.83 § 4.67 S2;C2;O1;T5
Scharpe 2008 2003–2004 Belgium RT 56 § 13 60/105 6.3(3.1,10.4) NA S3;C2;O3;T8
Quintana 2013 2009–2010 Spain HD 59.84 § 15 24/34 NA 3.83 § 4.70 S2;C2;O3;T7
PD 55.29 § 14.72 5/9 NA 2.08 § 1.1
RT 54.04 § 12.04 26 % 26 6.88 § 7.28 NA
Brakemeier 2012 2009–2010 Germany RT 52.2 § 15 NA >=0.5 NA S1;C2;O3;T6
Le Corre 2012 2009–2010 France RT 50.9(20,64) 32/89 3.4 (0.5,31) NA S2;C2;O3;T7
Note: HD, hemodialysis; HD_C, control group who was hemodialysis patient receiving one dose of vaccine;
PD, peritoneal dialysis; RT, renal transplant; F/M, female/male; NA, not available;
NOS, the Newcastle–Ottawa Scale for cohort studies; SN, the number of stars for cohort selection section;
CN, the number of stars for cohort comparability section; ON, the number of stars for cohort outcome section;
TN, the total number of stars.
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(Table 2). The formation of inﬂuenza vaccine was subunit
85 and split. MF-59 and AS03A adjuvant was applied in 3
studies.8,12,13 The interval between the ﬁrst and booster vac-
cination ranged from 28–90 d. The interval between vacci-
nation and serology was 21–30 d. The dosage of inﬂuenza
vaccine in 8 eligible studies was 15 mg for each virus strain.
90 In the other 2 studies, the dosage of H1N1 vaccine was
3.75 mg.
Risk of bias assessment
Several aspects of the study might have caused bias. Booster
vaccination might have a distinct inﬂuence on patients with
95 different renal conditions. The interval between the ﬁrst and
booster vaccination was different in the eligible studies. Dif-
ferent schedules for booster vaccination may have diverse
efﬁcacy. Different formations of the vaccine could produce
inconsistent immunogenicity. Age is also a signiﬁcant factor
100 which affects the immunogenicity of a vaccine. The age of
the patients was heterogeneous in different groups. Years on
dialysis might have an effect on the immune system. The
patients with different years on dialysis might have various
humoral responses to the inﬂuenza vaccine. Because of possi-
105 ble risk of bias from above sources, subgroup analysis for
H1N1 vaccine was performed to determine them. Subgroup
analysis showed they did not induce bias (data shown in
Table 3).
The efﬁcacy of the booster vaccination could not inﬂuence
110 publication because negative and positive results have equal
research value. After analysis, all the evidence from funnel plots
and the Egger’s test showed that there was no publication bias
in the meta-analysis (data not shown).
Efﬁcacy of booster vaccination in patients with HD, PD
115and RT
Eight hundred eighty-four patients in the current study had
detailed information about the immunogenicity of the ﬁrst
dose of the inﬂuenza vaccine. For each virus strain of inﬂuenza
vaccine, a serologic response of approximately 72% of the
120patients reached sero-protection (HI antibody titer >40). The
sero-protection rates in the patients met the Committee for
Proprietary Medical Products (CPMP) criteria.14
The rate difference (RD) for sero-protection (ﬁrst vs. booster
vaccination) was used to measure the efﬁcacy of an additional
125dose of the inﬂuenza vaccine. The pooled results showed (Fig. 2)
that the booster vaccination could not signiﬁcantly increase the
sero-protection rate in patients with HD, PD and RT. The pooled
RD for the H1N1 vaccine was 0.02 (95% conﬁdence interval
(CI): ¡0.02–0.06). For the H3N2 vaccine, the pooled RD was
1300.05 (95% CI: ¡0.01–0.11). For the B-type inﬂuenza vaccine, the
pooled RD was 0.04 (95% CI:¡0.02–0.10).
In order to better understand the efﬁcacy of booster vaccina-
tion in dialysis patients and renal allograft recipients, fold-
increase in geometric mean titer (GMT) from pre-booster to
135post-booster time point was also taken into consideration. The
fold-increase in GMT was 0.24(95% CI:0.09–0.39) For the
H1N1 vaccine, 0.50(95% CI:0.17–0.84) for the H3N2 vaccine,
0.06(95% CI:¡0.07–0.31) for the B-type vaccine.
Discussion
140Our ﬁndings showed that a single dose of inﬂuenza vaccine
induces a sub-optimal immune response, and the effect reaches
the CPMP criteria. Thus, a single dose of inﬂuenza vaccine is
Table 2. Information of vaccine used in the eligible studies and the immunogenicity.
GMT
First Author vaccine formation vaccine strains
dosage
(ug)
interval between the
ﬁrst and the boost dose
one
dose
booster
dose
fold increase
in GMT
Beyer split trivalent vaccine A/Chile/1/83(H1N1) 15 30 days NA NA NA
A/Pilippines/2/82(H3N2) 15 NA NA NA
B/USSR/100/83 15 NA NA NA
Vogtlander subunit trivalent vaccine A/Beijing/262/95(H1N1) 15 56 days 46 53.4 0.16
A/Sydney/5/97(H3N2) 15 36.4 60.9 0.67
B/Beijing/184/93 15 46 47.2 0.03
Tanzi subunit trivalent A/NewCaledonia/20/99 (H1N1) 15 30 days 52 61.5 0.18
MF59-adjuvanted vaccine A/Panama/2007/99(H3N2) 15 44 49 0.11
B/HongKong/330/2001 15 26.3 27.9 0.06
Song split trivalent vaccine A/New Caledonia/20/99 (H1N1) 15 28 days 21.54 24.28 0.13
A/Moscow/10/99 (H3N2) 15 37.13 64.09 0.73
B/HongKong/330/2001 15 25.62 21.14 0.83
Scharpe (2009) split trivalent vaccine A/New Caledonia/20/99 (H1N1) 15 90 days NA NA NA
A/Panama/2007/99 (H3N2) 15 NA NA NA
B/Shangdong/7/97 15 NA NA NA
Scharpe (2008) split trivalent vaccine A/New Caledonia/20/99 (H1N1) 15 90 days NA NA NA
A/Panama/2007/99 (H3N2) 15 NA NA NA
B/Shangdong/7/97 15 NA NA NA
Quintana split monovalent A%California%7% 2009(H1N1) 3.75 21 days 95.5 124.9 0.31(HD)
AS03A-adjuvanted vaccine 344.5 350.2 0.01(PD)
31.8 46.5 0.46(RT)
Brakemeier split monovalent
AS03A-adjuvanted vaccine
A%California%7%2009(H1N1) 3.75 21 § 3.5 days 46.3 67.4 0.46
Le Corre split monovalent vaccine A%California%7%2009(H1N1 15 21 days 47.6 59 0.23
Note: GMT, Geometric Mean Titer; NA, not available.
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capable of protecting patients with HD, PD and RT from inﬂu-
enza infection. After a booster dose of inﬂuenza vaccine was
145 administered to patients, the sero-protection rates increased;
however, a booster vaccination did not yield a satisfactory
immunopotentiating effect
An inﬂuenza vaccine is the most cost-effective way to pre-
vent inﬂuenza infection. An inﬂuenza vaccination can also sig-
150 niﬁcantly decrease the number of severe complications and
morality rate. It has been reported that inﬂuenza vaccine activ-
ity is 70%–90% in healthy populations >65 y of age.15 Our out-
comes showed that inﬂuenza vaccine activity was slightly
reduced in patients with HD, PD and RT. Therefore, the beneﬁ-
155 cial effect of inﬂuenza vaccine would also be realized in patients
with HD, PD and RT.
Booster vaccination has long been recommended to patients
with a compromised immune system to improve the level of
protection of patients with chronic renal disease; however, our
160 results showed that a booster dose of vaccine was not effective.
This ﬁnding does not mean that there is no beneﬁt of booster
vaccination in other populations. As Gueller et al. reported,16
after hematopoietic stem cell transplantation, patients beneﬁt
from a booster inﬂuenza vaccination. The potentiating effect of
165a booster dose inﬂuenza vaccine was also reported in liver
transplant recipients.17 Additional studies are needed to deter-
mine the efﬁcacy of booster vaccination in other populations,
such as the very elderly, HIV patients, and patients with auto-
immune disease.
170The sero-protection rate, mean fold increase in HI anti-
body titer, and sero-conversion rate are generally used to
describe the antibody response to an inﬂuenza vaccine. We
chose the sero-protection rate as the serologic parameter to
measure the immunogenicity of the inﬂuenza vaccine
175because of the public health objectives. HI titer of 40 is gen-
erally accepted to represent a 50% protective titer for
seasonal inﬂuenza A viruses in adult populations. The sero-
conversion rate and mean fold increase in HI antibody are
only related to the immunologic response and cannot assess
180the economic effectiveness in a population.
An annual inﬂuenza vaccine has been recommended, thus a
portion of patients with HD, PD and RT had pre-vaccination
antibody to the vaccine antigen. In this study we could not
assess the inﬂuence of pre-vaccination because of lacking ade-
185quate information about the baseline HI titer. One may ponder
the effect of the baseline HI titer on assessing the efﬁcacy of a
Figure 2. Forest plot of the efﬁcacy of a booster (H1N1) inﬂuenza vaccine in patients with HD, PD and RT.
Table 3. Rate difference of Sero-protection (H1N1) by subgroup analysis.
booster dose one dose
subgroup
numuber
of group events tatol events tatol
rate difference
(95%CI)
Test for subgroup
difference (P value)
overall 12 584 775 652 884 0.02 [¡0.02, 0.06] NA
Renal conditions
PD 2 30 33 27 33 0.09 [¡0.08, 0.26] 0.73
HD 6 290 390 368 497 0.02 (¡0.04, 0.07)
RT 4 264 352 257 354 0.02 [¡0.04, 0.08]
Interval between the ﬁrst and booster vaccination
230 9 314 464 302 474 0.04 [¡0.02, 0.10] 0.27
>30 3 270 311 350 410 0.00 [¡0.05, 0.05]
Formation of vaccine
subunit 9 485 628 553 729 0.02 [¡0.02, 0.06] 0.67
split 3 99 147 99 155 0.04 [¡0.05, 0.14]
Mean or median age
250 4 148 227 149 234 0.02 [¡0.06, 0.10] 0.96
>50 8 436 548 503 650 0.02 [¡0.02, 0.07]
Mean or median years on dialysis
22.5 3 163 204 240 303 0.01 [¡0.06, 0.08] 0.66
>2.5 4 143 205 142 213 0.03 [¡0.05, 0.12]
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booster vaccination; however, the situation that a part of the
patients had pre-vaccination was close to an actual real-life sit-
uation. One research by Agnieszka Mastalerz-Migas et al. may
190 help us to eliminate above concern.18 They concluded that
although inﬂuenza vaccination in previous seasons leads to
higher baseline HI titer, it is of little inﬂuence on immunores-
ponse to current inﬂuenza immunization in the dialysis
patients.
195 On the basis of our ﬁndings, we believe it is not prudent to
recommend a booster inﬂuenza vaccination in patients with
chronic renal disease. A booster dose of inﬂuenza vaccine
would result in wasting the limited antibody supply. Our ﬁnd-
ings would reduce an excess dose of inﬂuenza vaccine being
200 offered to patients. Although patients with chronic renal dis-
ease have impaired immune response to the inﬂuenza vaccine,
one dose of inﬂuenza vaccine is protective. This phenomenon
should attract us to further consider whether or not other
efforts on improving the immunogenicity of inﬂuenza vaccine
205 in patients are cost-effective.
The present meta-analysis had several limitations. Firstly,
sero-protection rate did not completely demonstrate the actual
effectiveness of booster vaccination. It is a great challenge to
directly assess the actual effectiveness because lacking related
210 studies. Sero-protection rate is an indirect parameter to show
the actual effectiveness of vaccine, for at least 50% of vaccinees
are protected when the HI titer is >40. Second, Subgroup
analysis was performed only on the H1N1 vaccine. Without
enough information about the other strain vaccine in the
215 included studies, the present data was difﬁcult to be divided
into subgroups.
Conclusion
Although the inﬂuenza vaccine had impaired immunogenicity,
one dose of inﬂuenza vaccine induced an adequate immune
220 response in the patients. A booster dose of the inﬂuenza vaccine
did not effectively enhance immunogenicity. Therefore, a
booster dose of vaccine is not recommended for in patients
with hemodialysis, peritoneal dialysis and renal transplant
recipients.
225Methods
Retrieval strategy and selection criteria
We searched PubMed, Embase, the Cochrane Library, the
China National Knowledge Infrastructure, and Science Direct
databases for articles published before January 2016. The key
230words used in the retrieval process were inﬂuenza vaccine,
inﬂuenza vaccination, dialysis, hemodialysis, continuous ambu-
latory peritoneal dialysis, CAPD, peritoneal dialysis, renal fail-
ure, chronic renal failure, chronic kidney disease, chronic renal
insufﬁciency, end stage renal disease, ESRD, and CKD. The
235articles were independently screened by 2 reviewers (YPL and
XJX) in the sequence of title, abstract, and full text. Disagree-
ments were resolved by discussion until consensus was
achieved. An eligible study must have met the inclusion criteria,
as follows: studies involving patients with chronic renal diseases
240who received an inﬂuenza vaccination; the study outcome was
hemagglutination-inhibiting (HI) antibody against inﬂuenza
virus; a comparison of the immunogenicity of the inﬂuenza
vaccine was made between the standard and booster vaccina-
tion in the same or a different group of patients. The exclusion
245criteria were as follows: study sample size <5; not clear and
original data; and duplicated data.
Data abstraction and quality assessment
We discussed which data we needed from each article and
designed a questionnaire to survey the articles. The extracted
250information included the following: authors’ names; publica-
tion year; study design; sample size; age of patients; years on
Figure 4. Forest plot of the efﬁcacy of a booster (B-type) inﬂuenza vaccine in patients with HD, PD and RT.
Figure 3. Forest plot of the efﬁcacy of a booster (H3N2) inﬂuenza vaccine in patients with HD, PD and RT.Q4
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dialysis; and vaccine type. The outcome that we abstracted
from the articles was the sero-protection rate. The sero-pro-
tection rate is a percentage of vaccine recipients with a
255 serum HI titer >1:40 after vaccination. A HI titer >1:40 can
be viewed as protective in healthy adults.19 Study quality was
assessed using the Newcastle–Ottawa Scale.20 The full NOS
score was 9 stars which consist of 3 stars from section of
cohort selection, 4 stars from section of comparability, and 3
260 stars from section of outcome. At least 2 researchers (XJX,
YPL, and ZFL) independently ﬁnished extraction and quality
assessment after reviewing each article. If there were discrep-
ancies during the abstraction and assessment process
between the reviewers, the discrepancies were resolved by
265 discussion.
Data analysis
This systematic review was performed according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
analysis statement.21 We pooled the outcomes using the Man-
270 tel–Haenszel ﬁxed or random model.22 Selection of the ﬁxed-
or random-effects model depended on the result of the
Cochrane’s Q test. Heterogeneity was signiﬁcant when the p
value of the Cochrane’s Q test was >10%.23 When the hetero-
geneity was signiﬁcant, the Mantel–Haenszel random model
275 was used. If not, we preferred the Mantel–Haenszel ﬁxed
model. The I2 value indicated the degree of inconsistency
among the studies, as follows 24: <25%, homogeneity;
25%–50%, moderate heterogeneity; 50%–75%, large heteroge-
neity; and >75%, extreme heterogeneity.25 Publication bias was
280 assessed through visual inspection of funnel plot asymmetry.
Asymmetry was also tested by Egger’s linear regression analy-
sis.26 Statistical analysis was performed using RevMan version
5.2 (provided by the Cochrane Collaboration) and STATA 13
(StataCorp, College Station, TX, USA).
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